Protagonist Therapeutics, Inc.
PTGX
$96.75
$4.394.75%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -130.15M | 45.91M | 52.04M | 56.19M | 275.19M |
| Total Depreciation and Amortization | 1.28M | 2.68M | 2.86M | 2.88M | 2.90M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 40.33M | 35.72M | 34.18M | 32.46M | 28.68M |
| Change in Net Operating Assets | 146.21M | -18.85M | -49.54M | 245.41M | -122.61M |
| Cash from Operations | 57.67M | 65.47M | 39.54M | 336.94M | 184.15M |
| Capital Expenditure | -1.59M | -1.76M | -2.44M | -1.66M | -1.36M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -47.74M | -105.12M | -254.58M | -398.30M | -298.13M |
| Cash from Investing | -49.33M | -106.87M | -257.03M | -399.96M | -299.48M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 23.34M | 24.54M | 30.93M | 30.58M | 26.45M |
| Repurchase of Common Stock | -479.00K | -479.00K | -479.00K | -479.00K | -600.00K |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 22.86M | 24.06M | 30.45M | 30.10M | 25.85M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 31.20M | -17.35M | -187.04M | -32.92M | -89.48M |